COST-EFFECTIVENESS ANALYSIS OF COMPARING GEFITINIB VERSUS CARBOPLATIN–PACLITAXEL AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER WITH SENSITIVE EGFR GENE MUTATIONS FROM A CHINESE PERSPECTIVE
Author(s)
Zhan M, Zheng H, Xu T
West China Hospital of Sichuan University, Chengdu, China
BACKGROUND: Lung cancer is the leading cause of cancer death. Non-small cell Lung cancer (NSCLC) is the most common type of lung cancer, responsible for about 85% of the cases. EGFR tyrosine kinase inhibitors such as gefitinib improved survival for patients with NSCLC, but inevitably increased monetary burden. The people's Republic of China National Health and Family Planning Commission announced the results of the first batch of national drug price negotiations in 2016, the price of gefitinib cut over 50% OBJECTIVES: To evaluate the cost-effectiveness of gefitinib versus carboplatin–paclitaxel as first-Line therapy for advanced NSCLC with sensitive epidermal growth factor receptor (EGFR) gene mutations after cost reconciliation in china METHODS: A Markov decision tree based on NEJ002 study was created, comparing gefitinib to carboplatin–paclitaxel in as the first-line treatment for NSCLC harboring an EGFR mutations. Three health states (progression-free survival, progressive disease and death) were analyzed in a Markov model. The costs were calculated from the Chinese societal perspective. Results were reported in Quality-adjusted life year (QALY) and incremental cost-effectiveness ratios (ICERs) RESULTS: Gefitinib was estimated to increase the cost by $4757.02, with a gain of 0.26 QALY. Gefitinib came at an ICER of $18296.23 per QALY, which are less than the accepted willingness-to-pay (WTP) threshold of $23970.00 per QALY in China CONCLUSIONS: Gefitinib is a cost-effective first-line treatment for NSCLC with mutated EGFR when compared with carboplatin–paclitaxel in China.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PCN120
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology